AR051221A1 - Derivados de piridina su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de piridina su preparacion y su aplicacion en terapeutica

Info

Publication number
AR051221A1
AR051221A1 ARP050104331A ARP050104331A AR051221A1 AR 051221 A1 AR051221 A1 AR 051221A1 AR P050104331 A ARP050104331 A AR P050104331A AR P050104331 A ARP050104331 A AR P050104331A AR 051221 A1 AR051221 A1 AR 051221A1
Authority
AR
Argentina
Prior art keywords
group
unsubstituted
alkyl
atom
substituted
Prior art date
Application number
ARP050104331A
Other languages
English (en)
Inventor
Lionel Barre
Francis Barth
Christian Congy
Philippe Pointeau
Murielle Rinaldi-Carmona
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR051221A1 publication Critical patent/AR051221A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)

Abstract

Se refiere a derivados de piridina. Procedimientos de preparacion y aplicacion en terapéutica. Reivindicacion 1: Un compuesto que responde a la formula (1) en la que Z representa un grupo N(R1)XR2, N(R1)COOR'2 o OCON(R1)R'2; X representa un grupo - CO-, -SO2-, -CON(R10)- o -CSN(R10)-; R1 representa un átomo de H o un grupo alquilo C1-4; R2 representa un grupo alquilo C3-10 no sustituido o sustituido con un grupo CF3; un radical carbocíclico no aromático C3-12, no sustituido o sustituido una o varias veces con sustituyentes idénticos o diferentes elegidos entre un grupo alquilo C1-4, hidroxilo, alcoxi C1-4, alquiltio C1-4 o ciano; un radical heterocíclico de 4 a 8 átomos oxigenados, azufrado o nitrogenado, saturado o insaturado, no sustituido o sustituido con uno o varios sustituyentes idénticos o diferentes elegidos entre un átomo de halogeno, un grupo alquilo C1-4, hidroxilo, trifluorometilo, alcoxi C1-4, trifluorometoxi, alquiltio C1-4, ciano o nitro; un indolilo no sustituido o sustituido con un átomo de halogeno o con un grupo alquilo C1-4, trifluorometilo, hidroxilo, alcoxi C1-4, trifluorometoxi, alquiltio C1-4, ciano o nitro; un tetrahidro-1- o2-naftalenilo; un 1- o 2-naftalenilo; un benzotiofenilo o un benzofurilo; un fenilo no sustituido o sustituido una o varias veces con sustituyentes idénticos o diferentes elegidos entre un átomo de halogeno, un grupo alquilo C1-4, trifluorometilo, trifluorometoxi, hidroxilo alcoxi C1-4, ciano, nitro, alcanoilo C1-4, fenilo o un grupo S(O)nAlk o NR13R14; un benzodioxol; un fenoximetilo, 1-fenoxietilo o 1-metil-1-fenoxietilo, estando los grupos fenilo sin sustituir o sustituidos una o varias veces con sustituyentes idénticos o diferentes elegidos entre un átomo de halogeno, un grupo alquilo C1-4 o trifluorometilo; un fenilciclopropilo, estando el grupo fenilo sin sustituir o sustituido una o varias veces con sustituyentes idénticos o diferentes elegidos entre un átomo de halogeno, un grupo alquilo C1-4 o trifluorometilo; un alquileno C1-2 sustituido con uno o dos sustituyentes idénticos o diferentes elegidos entre: (i) un grupo alquilo C1-4; (ii) un radical carbocíclico no aromático C3-12 no sustituido o sustituido una o varias veces con un grupo alquilo C1-4; (iii) un fenilo no sustituido o sustituido con uno o varios sustituyentes, idénticos o diferentes, elegidos entre un átomo de halogeno, un grupo alquilo C1-4, hidroxilo, trifluorometilo, alcoxi C1-4, trifluorometoxi, alcanoilo C1-4, ciano, nitro, fenilo o un grupo S(O)nAlk o NR13R14; (iv) un radical heterocíclico de 4 a 8 átomos, oxigenado, azufrado o nitrogenado, saturado o insaturado, no sustituido o sustituido con uno o varios sustituyentes idénticos o diferentes elegidos entre un átomo de halogeno, un grupo alquilo C1-4 o trifluorometilo; además cuando X representa un grupo -CON(R10)- o -CSN(R10)-, R2 puede representar un grupo alcanoilo C1-6 o un grupo benzoilo o bencilcarbonilo, estando el grupo fenilo de dichos grupos no sustituido o sustituido con sustituyentes idénticos o diferentes elegidos entre un átomo de halogeno, un grupo alquilo C1-4 o trifluorometilo; R'2 representa un fenilo no sustituido o sustituido una o varias veces con sustituyentes idénticos o diferentes elegidos entre un átomo de halogeno o un grupo alquilo C1-4, trifluorometilo, ciano o nitro o alcoxi C1-4; R3 representa un átomo de H o un grupo alquilo C1-4, ciano, alcoximetilo C1-4 o hidroximetilo; R4, R5, R6, R7, R8 y R9 representan, cada uno independientemente uno de otro, un átomo de H o de halogeno, un grupo alquilo C1-6, alcoxi C1-6, trifluorometilo, trifluorometoxi, ciano, nitro o un grupo S(O)nAlk; R10 representa un átomo de H o un grupo alquilo C1-4; o R2 y R10 junto con el átomo de N al que están unidos constituyen un radical heterocíclico de 4 a 8 átomos, que contiene o no un segundo heteroátomo elegido entre un átomo de O, de S o de N, no sustituido o sustituido una o varias veces con un grupo alquilo C1-4, un grupo alcanoilo C1-4, un grupo NR11R12 o CONR11R12; un grupo fenilo no sustituido o sustituido una o varias veces con un átomo de halogeno, un grupo alquilo C1-4, alcoxi C1-4 o trifluorometilo; R11 y R12 representan, cada uno independientemente del otro, un átomo de H, un grupo alquilo C1-4, o R11 y R12 junto con el átomo de N al que están unidos constituyen un radical heterocíclico de 4 a 8 átomos; n representa 0, 1 o 2; R13 y R14 representan, cada uno independientemente del otro, un átomo de H o un grupo alquilo C1-4, o R13 y R14 junto con el átomo de N al que están unidos constituyen un radical heterocíclico saturado o insaturado de 4 a 8 átomos; Alk representa un grupo alquilo C1-4; con la condicion de que uno de los sustituyentes R1, R3, R5, R6, R8 o R9 sea diferente del H cuando R4 y R7 representan simultáneamente un grupo 4-metoxi; en estado de base o de sal de adicion, así como en estado de hidrato o de solvato.
ARP050104331A 2004-10-18 2005-10-17 Derivados de piridina su preparacion y su aplicacion en terapeutica AR051221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0411030A FR2876691B1 (fr) 2004-10-18 2004-10-18 Derives de pyridine, leur preparation, leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR051221A1 true AR051221A1 (es) 2006-12-27

Family

ID=34950592

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104331A AR051221A1 (es) 2004-10-18 2005-10-17 Derivados de piridina su preparacion y su aplicacion en terapeutica

Country Status (22)

Country Link
US (1) US20080021070A1 (es)
EP (1) EP1805143A1 (es)
JP (1) JP2008516934A (es)
KR (1) KR20070063008A (es)
CN (1) CN101039912A (es)
AR (1) AR051221A1 (es)
AU (1) AU2005296959A1 (es)
BR (1) BRPI0516926A (es)
CA (1) CA2582778A1 (es)
EA (1) EA200700891A1 (es)
EC (1) ECSP077400A (es)
FR (1) FR2876691B1 (es)
IL (1) IL182385A0 (es)
MA (1) MA29016B1 (es)
MX (1) MX2007004482A (es)
NO (1) NO20072454L (es)
NZ (1) NZ554952A (es)
PE (1) PE20060584A1 (es)
TN (1) TNSN07114A1 (es)
TW (1) TW200628450A (es)
UY (1) UY29163A1 (es)
WO (1) WO2006042955A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2899899A1 (fr) * 2006-04-14 2007-10-19 Sanofi Aventis Sa Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
FR2922209B1 (fr) * 2007-10-12 2010-06-11 Sanofi Aventis 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
AU2010247414B2 (en) 2009-05-15 2013-08-01 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
CN109476599A (zh) * 2016-07-29 2019-03-15 东丽株式会社 胍衍生物和其医药用途
WO2018159650A1 (ja) * 2017-02-28 2018-09-07 東レ株式会社 グアニジン誘導体及びその医薬用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2198737B1 (es) * 1972-09-13 1975-11-28 Serdex
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
JP2004517870A (ja) * 2001-01-02 2004-06-17 藤沢薬品工業株式会社 シクロオキシゲナーゼ阻害剤
CA2479744A1 (en) * 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) * 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant

Also Published As

Publication number Publication date
PE20060584A1 (es) 2006-08-18
IL182385A0 (en) 2007-07-24
EA200700891A1 (ru) 2007-08-31
BRPI0516926A (pt) 2008-09-23
TW200628450A (en) 2006-08-16
MX2007004482A (es) 2007-06-13
JP2008516934A (ja) 2008-05-22
US20080021070A1 (en) 2008-01-24
NZ554952A (en) 2009-08-28
EP1805143A1 (fr) 2007-07-11
CA2582778A1 (fr) 2006-04-27
TNSN07114A1 (fr) 2008-06-02
CN101039912A (zh) 2007-09-19
KR20070063008A (ko) 2007-06-18
NO20072454L (no) 2007-05-14
AU2005296959A1 (en) 2006-04-27
FR2876691B1 (fr) 2006-12-29
MA29016B1 (fr) 2007-11-01
UY29163A1 (es) 2006-04-28
WO2006042955A1 (fr) 2006-04-27
ECSP077400A (es) 2007-05-30
FR2876691A1 (fr) 2006-04-21

Similar Documents

Publication Publication Date Title
AR051221A1 (es) Derivados de piridina su preparacion y su aplicacion en terapeutica
AR048495A1 (es) Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk
AR060800A1 (es) Derivados de aminometilpiridina su preparacion y su aplicacion en terapeutica
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
AR055074A1 (es) Derivados de heteroaril benzamidas como activadores de glk en el tratamiento de diabetes. procesos de obtencion y composiciones farmaceuticas.
AR054799A1 (es) Derivados de oxindol
AR070193A1 (es) Terapia combinada que comprende inhibidores de sglt e inhibidores de dpp4, composicion farmaceutica y uso
AR048004A1 (es) Nuevos esteres de quinuclidina cuaternizados
AR067478A1 (es) Compuestos derivados de morfolina pirimidina
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR012825A1 (es) Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos
PE20060689A1 (es) Derivados de sulfonamidas como antagonistas de receptores orexina 2
AR048086A1 (es) Bencenodicarboxamidas insecticidas
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
ECSP066695A (es) Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1
AR052655A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina(amida,sulfonamida,carbamato,urea)
AR049965A1 (es) Moduladores de androgenos
HN2005000239A (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica
ATE434603T1 (de) Chinazolinderivate als antivirale mittel
AR063898A1 (es) Derivados de dihidro-h-pirazolo[4,3c]piridazin-3-ona sustituidos,metodo de preparacion,composiciones farmaceuticas que los contienen u usos en terapeutica para prevenir o tratar enfermedades en las que estan implicados receptores canabinoides cb1.
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal